Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE45.2300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots45.2400/ 1
- Ask / Lots47.9400/ 2
- Open / Previous Close45.6200 / 45.2300
- Day Range
- 52 Week Range
- Volume482,494
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 5931 | 46.34 |
| 09:34 ET | 300 | 45.85 |
| 09:36 ET | 300 | 45.36 |
| 09:38 ET | 425 | 45.17 |
| 09:39 ET | 200 | 45.28 |
| 09:41 ET | 862 | 45.435 |
| 09:43 ET | 1100 | 45.23 |
| 09:45 ET | 2127 | 45.445 |
| 09:48 ET | 1282 | 45.22 |
| 09:50 ET | 1200 | 45.285 |
| 09:52 ET | 500 | 45.29 |
| 09:54 ET | 1195 | 45.58 |
| 09:56 ET | 200 | 45.59 |
| 09:57 ET | 300 | 45.64 |
| 09:59 ET | 1264 | 45.71 |
| 10:01 ET | 600 | 45.775 |
| 10:03 ET | 2200 | 45.76 |
| 10:06 ET | 100 | 45.765 |
| 10:08 ET | 500 | 45.87 |
| 10:10 ET | 1200 | 45.87 |
| 10:12 ET | 400 | 45.79 |
| 10:14 ET | 1212 | 45.8 |
| 10:15 ET | 300 | 45.89 |
| 10:17 ET | 650 | 45.87 |
| 10:19 ET | 500 | 45.95 |
| 10:21 ET | 1428 | 45.975 |
| 10:24 ET | 500 | 46.06 |
| 10:26 ET | 200 | 45.99 |
| 10:28 ET | 1000 | 45.67 |
| 10:30 ET | 994 | 45.57 |
| 10:32 ET | 200 | 45.655 |
| 10:33 ET | 702 | 45.63 |
| 10:37 ET | 1400 | 45.87 |
| 10:39 ET | 200 | 45.87 |
| 10:42 ET | 300 | 45.995 |
| 10:44 ET | 1007 | 45.955 |
| 10:46 ET | 300 | 45.985 |
| 10:48 ET | 200 | 46.0275 |
| 10:50 ET | 100 | 46.07 |
| 10:51 ET | 300 | 46.015 |
| 10:53 ET | 400 | 46.21 |
| 10:55 ET | 338 | 46.21 |
| 10:57 ET | 100 | 46.25 |
| 11:00 ET | 200 | 46.23 |
| 11:02 ET | 300 | 46.19 |
| 11:04 ET | 100 | 46.15 |
| 11:06 ET | 400 | 46.04 |
| 11:08 ET | 300 | 46.12 |
| 11:09 ET | 900 | 46.0301 |
| 11:11 ET | 200 | 46.09 |
| 11:13 ET | 2343 | 45.905 |
| 11:15 ET | 300 | 45.93 |
| 11:18 ET | 400 | 46 |
| 11:20 ET | 800 | 46.07 |
| 11:22 ET | 260 | 46.021 |
| 11:24 ET | 300 | 46.09 |
| 11:26 ET | 200 | 46.11 |
| 11:27 ET | 100 | 46.11 |
| 11:29 ET | 1331 | 46.185 |
| 11:31 ET | 200 | 46.25 |
| 11:33 ET | 1141 | 46.215 |
| 11:40 ET | 3467 | 46.14 |
| 11:42 ET | 712 | 46.135 |
| 11:44 ET | 200 | 46.03 |
| 11:45 ET | 787 | 46.04 |
| 11:47 ET | 1324 | 46.11 |
| 11:49 ET | 234 | 46.04 |
| 11:51 ET | 300 | 46.06 |
| 11:54 ET | 200 | 46.1 |
| 11:56 ET | 840 | 46.03 |
| 11:58 ET | 758 | 46.12 |
| 12:00 ET | 101 | 46.03 |
| 12:02 ET | 1483 | 45.965 |
| 12:03 ET | 200 | 45.885 |
| 12:05 ET | 200 | 45.73 |
| 12:07 ET | 700 | 45.77 |
| 12:09 ET | 100 | 45.73 |
| 12:12 ET | 300 | 45.75 |
| 12:14 ET | 400 | 45.67 |
| 12:16 ET | 511 | 45.63 |
| 12:18 ET | 200 | 45.53 |
| 12:20 ET | 622 | 45.5 |
| 12:21 ET | 400 | 45.52 |
| 12:23 ET | 1776 | 45.585 |
| 12:25 ET | 100 | 45.58 |
| 12:27 ET | 300 | 45.56 |
| 12:30 ET | 100 | 45.58 |
| 12:34 ET | 409 | 45.44 |
| 12:36 ET | 200 | 45.45 |
| 12:38 ET | 1100 | 45.4 |
| 12:39 ET | 300 | 45.43 |
| 12:41 ET | 500 | 45.45 |
| 12:43 ET | 468 | 45.41 |
| 12:45 ET | 612 | 45.29 |
| 12:48 ET | 300 | 45.35 |
| 12:50 ET | 1000 | 45.345 |
| 12:52 ET | 300 | 45.39 |
| 12:54 ET | 200 | 45.41 |
| 12:56 ET | 100 | 45.395 |
| 12:57 ET | 552 | 45.4 |
| 12:59 ET | 100 | 45.35 |
| 01:01 ET | 350 | 45.3554 |
| 01:03 ET | 681 | 45.35 |
| 01:06 ET | 100 | 45.31 |
| 01:08 ET | 820 | 45.25 |
| 01:10 ET | 2930 | 45.1 |
| 01:12 ET | 3048 | 45.21 |
| 01:14 ET | 1410 | 45.29 |
| 01:15 ET | 702 | 45.32 |
| 01:17 ET | 300 | 45.33 |
| 01:21 ET | 800 | 45.37 |
| 01:24 ET | 436 | 45.32 |
| 01:26 ET | 327 | 45.335 |
| 01:28 ET | 100 | 45.43 |
| 01:30 ET | 100 | 45.42 |
| 01:32 ET | 728 | 45.45 |
| 01:33 ET | 3100 | 45.535 |
| 01:35 ET | 200 | 45.57 |
| 01:37 ET | 100 | 45.51 |
| 01:39 ET | 1028 | 45.63 |
| 01:42 ET | 300 | 45.68 |
| 01:44 ET | 200 | 45.68 |
| 01:46 ET | 2475 | 45.65 |
| 01:48 ET | 6404 | 45.595 |
| 01:50 ET | 2891 | 45.6 |
| 01:51 ET | 2764 | 45.74 |
| 01:57 ET | 400 | 45.78 |
| 02:00 ET | 600 | 45.74 |
| 02:04 ET | 100 | 45.78 |
| 02:06 ET | 200 | 45.78 |
| 02:08 ET | 400 | 45.72 |
| 02:09 ET | 1202 | 45.88 |
| 02:11 ET | 100 | 45.92 |
| 02:13 ET | 1328 | 46 |
| 02:15 ET | 688 | 46.03 |
| 02:18 ET | 544 | 45.95 |
| 02:20 ET | 100 | 45.99 |
| 02:22 ET | 400 | 45.98 |
| 02:24 ET | 1200 | 45.91 |
| 02:26 ET | 100 | 45.905 |
| 02:27 ET | 950 | 45.96 |
| 02:29 ET | 420 | 46.0199 |
| 02:31 ET | 1750 | 45.915 |
| 02:33 ET | 100 | 45.96 |
| 02:36 ET | 26421 | 45.76 |
| 02:38 ET | 300 | 45.815 |
| 02:40 ET | 1000 | 45.89 |
| 02:42 ET | 100 | 45.94 |
| 02:44 ET | 1500 | 45.98 |
| 02:47 ET | 100 | 45.92 |
| 02:49 ET | 200 | 45.98 |
| 02:51 ET | 14845 | 45.83 |
| 02:54 ET | 300 | 45.805 |
| 02:56 ET | 800 | 45.76 |
| 02:58 ET | 600 | 45.625 |
| 03:00 ET | 300 | 45.62 |
| 03:02 ET | 888 | 45.62 |
| 03:03 ET | 352 | 45.59 |
| 03:05 ET | 1628 | 45.63 |
| 03:07 ET | 869 | 45.48 |
| 03:09 ET | 400 | 45.48 |
| 03:12 ET | 700 | 45.42 |
| 03:14 ET | 400 | 45.42 |
| 03:16 ET | 400 | 45.41 |
| 03:18 ET | 1000 | 45.45 |
| 03:20 ET | 500 | 45.47 |
| 03:21 ET | 1020 | 45.47 |
| 03:23 ET | 200 | 45.51 |
| 03:27 ET | 525 | 45.45 |
| 03:30 ET | 2541 | 45.52 |
| 03:32 ET | 2120 | 45.57 |
| 03:34 ET | 2850 | 45.45 |
| 03:36 ET | 888 | 45.5 |
| 03:38 ET | 500 | 45.47 |
| 03:39 ET | 400 | 45.44 |
| 03:41 ET | 1721 | 45.395 |
| 03:43 ET | 3757 | 45.4 |
| 03:45 ET | 2009 | 45.32 |
| 03:48 ET | 1200 | 45.34 |
| 03:50 ET | 1272 | 45.35 |
| 03:52 ET | 5008 | 45.365 |
| 03:54 ET | 4344 | 45.38 |
| 03:56 ET | 4620 | 45.38 |
| 03:57 ET | 35565 | 45.2 |
| 03:59 ET | 105290 | 45.23 |
Jun 15, 2024
Agios Presents Positive Results from Phase 3 -2-, from 8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
8:45AM ET on Saturday Jun 15, 2024 by Dow Jones
Jun 13, 2024
DJ Agios Pharmaceuticals Price Target Announced at $46.00/Share by JP Morgan, from 5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
5:17PM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 6, 2024
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET, from 9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
9:00AM ET on Thursday Jun 06, 2024 by Dow Jones
Jun 4, 2024
DJ Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 11:26AM ET on Tuesday Jun 04, 2024 by Dow Jones
11:26AM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
DJ Agios Pharmaceuticals Shares Rise 16% After Positive Trial Data for Mitapivat, from 10:25AM ET on Monday Jun 03, 2024 by Dow Jones
10:25AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.6B | -7.2x | --- |
Structure Therapeutics Inc | 2.6B | -18.8x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.0x | --- |
IDEAYA Biosciences Inc | 2.8B | -18.5x | --- |
MoonLake Immunotherapeutics | 2.5B | -51.6x | --- |
Intellia Therapeutics Inc | 2.3B | -4.7x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 56.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-6.31 |
Book Value | $14.50 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 87.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,336.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
